USA PPI (MoM) for Jun 1.100% vs 0.800% consensus estimate. The prior reading was 0.900%.
Goldman Sachs Maintains Buy on Kronos Bio, Lowers Price Target to $14
Goldman Sachs analyst Salveen Richter maintains Kronos Bio (NASDAQ:KRON) with a Buy and lowers the price target from $25 to $14.